Facts and figures Lung cancer has become the most frequent malignant neoplasm among men in most countries and represents the most important cause of cancer death worldwide. Survival from lung cancer is poor (5–10% at five years). • Worldwide, it accounts for an estimated 960 000 new cases and 850 000 deaths each year among [...]
• Small-cell lung cancer (SCLC) accounts for 15-18% of all lung cancer cases. • The incidence of SCLC has decreased in recent years. • There are 2 stages of SCLC, limited disease and extensive disease. • SCLC is strongly associated with tobacco smoking. Limited disease Limited disease is defined as a tumour, which can be [...]
Non-small-cell lung cancer (NSCLC) accounts for 80% of lung cancer cases. Pathological diagnosis should be made according to the WHO classification. The main NSCLC tumour groups are: • Adenocarcinoma • Squamous cell carcinoma • Large-cell carcinoma Patients with NSCLC are staged according to the UICC 6 system and grouped into risk categories as shown in [...]
h3. Interactions of docetaxel with other medicinal products and other forms of interaction Docetaxel is a taxane antineoplastic agent with anti-mitotic activity. It is indicated for the treatment of non-small cell lung cancer, breast cancer, head and neck cancer and gastric adenocarcinoma. The metabolism of docetaxel involves CYP3A4 as a major metabolic pathway. Caution should [...]
Results from the RIBBON 2 study presented at the 32nd Annual San Antonio Breast Cancer Symposium in December 2009 suggest a potential new role for bevacizumab as second-line treatment in advanced breast cancer.(1) Despite the treatment improvements that have already been made, breast cancer continues to be the leading cause of cancer death in women [...]
Roche wish to announce that the European Commission has approved Herceptin (trastuzumab) in combination with capecitabine or 5-fluorouracil and cisplatin for use in patients with HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The approval is based on the strong results from the [...]
Pfizer Healthcare Ireland are pleased to announce the approval of Torisel for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The recent approval was based on results of a phase III clinical study that showed patients with relapsed and/or refractory MCL treated with Torisel experienced a statistically significant improvement in [...]
The Irish Medicines Board wishes to communicate the outcome of an EU review of recent epidemiological evidence which suggests a possible small increased risk of congenital cardiac defects in association with fluoxetine in early pregnancy, similar to that seen with paroxetine. There are insufficient data to draw conclusions on whether there is a similar risk [...]
Fentanyl is a potent opioid analgesic and is a controlled drug in Ireland. Fentanyl patches (1) are authorised for the management of malignant and non-malignant chronic intractable pain and a 25 micrograms (µg) per hour fentanyl patch equates to a daily dose of oral morphine of up to 90mg. Fentanyl patches should be used only [...]
Company: Ranbaxy Ireland. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Alfuzosin (HCl) 10mg. Description: White to off-white, round, uncoated, biconvex, prolonged release tablets marked with RY 10 on one side. Presentation: 10mg-30, €21.75. Indications: Treatment of moderate to severe functional symptoms of benign prostate hyperplasia (BPH). Pharmacology: Alfuzosin is an orally active α-adrenoreceptor antagonist [...]
Loading ...
